PMID- 28819566
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2090-004X (Print)
IS  - 2090-0058 (Electronic)
IS  - 2090-004X (Linking)
VI  - 2017
DP  - 2017
TI  - Development of Poly Lactic/Glycolic Acid (PLGA) Microspheres for Controlled 
      Release of Rho-Associated Kinase Inhibitor.
PG  - 1598218
LID - 10.1155/2017/1598218 [doi]
LID - 1598218
AB  - PURPOSE: The purpose of this study was to investigate the feasibility of poly 
      lactic/glycolic acid (PLGA) as a drug delivery carrier of Rho kinase (ROCK) 
      inhibitor for the treatment of corneal endothelial disease. METHOD: ROCK 
      inhibitor Y-27632 and PLGA were dissolved in water with or without gelatin (W1), 
      and a double emulsion [(W1/O)/W2] was formed with dichloromethane (O) and 
      polyvinyl alcohol (W2). Drug release curve was obtained by evaluating the 
      released Y-27632 by using high performance liquid chromatography. PLGA was 
      injected into the anterior chamber or subconjunctiva in rabbit eyes, and ocular 
      complication was evaluated by slitlamp microscope and histological analysis. 
      RESULTS: Y-27632 incorporated PLGA microspheres with different molecular weights, 
      and different composition ratios of lactic acid and glycolic acid were 
      fabricated. A high molecular weight and low content of glycolic acid produced a 
      slower and longer release. The Y-27632 released from PLGA microspheres 
      significantly promoted the cell proliferation of cultured corneal endothelial 
      cells. The injection of PLGA did not induce any evident eye complication. 
      CONCLUSIONS: ROCK inhibitor-incorporated PLGA microspheres were fabricated, and 
      the microspheres achieved the sustained release of ROCK inhibitor over 7-10 days 
      in vitro. Our data should encourage researchers to use PLGA microspheres for 
      treating corneal endothelial diseases.
FAU - Koda, Sho
AU  - Koda S
AD  - Department of Biomedical Engineering, Faculty of Life and Medical Sciences, 
      Doshisha University, Kyotanabe 610-0321, Japan.
AD  - Laboratory of Biomaterials, Department of Regeneration Science and Engineering, 
      Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawara-cho 
      Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Okumura, Naoki
AU  - Okumura N
AUID- ORCID: 0000-0003-2275-5263
AD  - Department of Biomedical Engineering, Faculty of Life and Medical Sciences, 
      Doshisha University, Kyotanabe 610-0321, Japan.
FAU - Kitano, Junji
AU  - Kitano J
AD  - Department of Biomedical Engineering, Faculty of Life and Medical Sciences, 
      Doshisha University, Kyotanabe 610-0321, Japan.
FAU - Koizumi, Noriko
AU  - Koizumi N
AUID- ORCID: 0000-0002-6940-1334
AD  - Department of Biomedical Engineering, Faculty of Life and Medical Sciences, 
      Doshisha University, Kyotanabe 610-0321, Japan.
FAU - Tabata, Yasuhiko
AU  - Tabata Y
AUID- ORCID: 0000-0002-7344-8477
AD  - Laboratory of Biomaterials, Department of Regeneration Science and Engineering, 
      Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawara-cho 
      Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170727
PL  - United States
TA  - J Ophthalmol
JT  - Journal of ophthalmology
JID - 101524199
PMC - PMC5551544
EDAT- 2017/08/19 06:00
MHDA- 2017/08/19 06:01
PMCR- 2017/07/27
CRDT- 2017/08/19 06:00
PHST- 2017/02/07 00:00 [received]
PHST- 2017/06/21 00:00 [revised]
PHST- 2017/07/09 00:00 [accepted]
PHST- 2017/08/19 06:00 [entrez]
PHST- 2017/08/19 06:00 [pubmed]
PHST- 2017/08/19 06:01 [medline]
PHST- 2017/07/27 00:00 [pmc-release]
AID - 10.1155/2017/1598218 [doi]
PST - ppublish
SO  - J Ophthalmol. 2017;2017:1598218. doi: 10.1155/2017/1598218. Epub 2017 Jul 27.